$CMMB It will be weird if the next 2 months pass without any bids from BP. nebokitug is the only one that have dual action and attack both inflammation and fibrosis. Its rare, especially in a $30B market like RA where there are few treatments available. I would really like to
$CMMB Looks like first phase of accumulation was finished last week.
Now we await publication of S-4 depending on if SEC finds the application good enough. That will be bullish for the merger and we can finally move on to voting. šš»
$CMMB Someone sold 13k shares. $2.74 - $2.65. The higher the price goes, the more expensive it becomes to borrow. The 141% fee stings a bit. Shorts are getting desperate
Price bumped right up to $2.74 again. Someone is accumulating while retail sell for peanuts. A tale as old as
$CMMB Risk vs Reward, Chemomab is a very sweet investment, probably the best in biotech right now.
This could go so many ways, most of them are very rewarding for investors and the company.
PSC outlicensing? Instant $5 per ADS for shareholders and massive upfront payment
$CMMB Huge buy blocks from the start on Chemomab. Someone in the know? š
Could be biotech biggest opportunity of 2026.
NFA. Im just trusting my instincts šš»
$CMMB I have a good feeling Chemomab is a target for aquisition here with nebokitug.
Far far less potent drugs and molecules much less developed have had big bids when a merger is up on hand and close.
šš»
$CMMB I sent email to Abbvie, Roche, Ipsen and Gilead today about Chemomab and the opportunity of partnering for PSC or going for outright aquisition for big bang for the buck for nebokitug.
Its a longshot, but they get probably drowned by a lot of spam and other request every
